Skip to main content

Von Willebrand Disease

9
Pipeline Programs
8
Companies
20
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
5
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

CSL Seqirus
CSL SeqirusUK - Maidenhead
10 programs
1
2
2
Blood coagulation Factor VIII and vWF, humanPhase 4
VoncentoPhase 4
BiostatePhase 3
BiostatePhase 3
Biostate®Phase 2/3
+5 more programs
Biocorp
BiocorpFrance - Issoire
3 programs
3
OptivatePhase 31 trial
OptivatePhase 31 trial
Optivate®Phase 31 trial
Active Trials
NCT00387192Terminated26Est. Sep 2008
NCT00404300Terminated25Est. Sep 2008
NCT02246881Completed
Pfizer
PfizerNEW YORK, NY
1 program
1
recombinant interleukin-11Phase 21 trial
Active Trials
NCT00151125Completed12Est. Dec 2007
CSL Behring
CSL BehringIL - Bradley
10 programs
A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)N/A1 trial
National Study of Moderate and Severe Von Willebrand Disease in the NetherlandsN/A1 trial
VWF/FVIII productsN/A1 trial
Von Willebrand Disease in the NetherlandsN/A1 trial
Voncento®N/A1 trial
+5 more programs
Active Trials
NCT00701545Completed21Est. Apr 2009
NCT00510042Completed1,100Est. Sep 2009
NCT00557908Completed105Est. Feb 2013
+5 more trials
Octapharma
OctapharmaAustria - Vienna
2 programs
Patients using Wilate as standard of careN/A1 trial
WilatePHASE_31 trial
Active Trials
NCT01602419Completed120Est. Apr 2018
NCT04953884Completed12Est. Dec 2024
Takeda
TakedaTOKYO, Japan
2 programs
Recombinant von Willebrand factor : recombinant FVIIIPHASE_11 trial
Recombinant von Willebrand FactorPHASE_31 trial
Active Trials
NCT00816660Completed32Est. Aug 2010
NCT02283268Completed24Est. Jul 2016
Parexel
ParexelMA - Boston
2 programs
Biostate®PHASE_2_31 trial
BiostatePHASE_31 trial
Active Trials
NCT00941616Completed22Est. Feb 2012
NCT01213446Completed17Est. Aug 2013
Grifols
GrifolsNEW YORK, NY
2 programs
Alphanate SD/HTPHASE_41 trial
plasma-derived FVIII/VWF concentratePHASE_41 trial
Active Trials
NCT00555555Active Not Recruiting15Est. Mar 2029
NCT02472665Recruiting8Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
CSL BehringVoncento
Grifolsplasma-derived FVIII/VWF concentrate
GrifolsAlphanate SD/HT
CSL BehringBlood coagulation Factor VIII and vWF, human
OctapharmaWilate
TakedaRecombinant von Willebrand Factor
CSL BehringBiostate
ParexelBiostate
BiocorpOptivate
BiocorpOptivate
BiocorpOptivate®
ParexelBiostate®
Pfizerrecombinant interleukin-11
TakedaRecombinant von Willebrand factor : recombinant FVIII
CSL BehringVon Willebrand Disease in the Netherlands

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 2,850 patients across 20 trials

NCT02552576CSL BehringVoncento

Study of Voncento® in Subjects With Von Willebrand Disease

Start: Oct 2015Est. completion: Feb 201826 patients
Phase 4Completed
NCT02472665Grifolsplasma-derived FVIII/VWF concentrate

Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease

Start: Dec 2013Est. completion: Dec 20268 patients
Phase 4Recruiting
NCT00555555GrifolsAlphanate SD/HT

Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients

Start: Sep 2007Est. completion: Mar 202915 patients
Phase 4Active Not Recruiting
NCT00168090CSL BehringBlood coagulation Factor VIII and vWF, human

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

Start: Oct 2001Est. completion: May 200630 patients
Phase 4Completed
NCT04953884OctapharmaWilate

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age

Start: Sep 2021Est. completion: Dec 202412 patients
Phase 3Completed
NCT02283268TakedaRecombinant von Willebrand Factor

Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery

Start: Apr 2015Est. completion: Jul 201624 patients
Phase 3Completed
NCT01224808CSL BehringBiostate

Extension Study of Biostate in Subjects With Von Willebrand Disease

Start: Oct 2010Est. completion: Mar 201420 patients
Phase 3Completed
NCT01213446ParexelBiostate

Study of Biostate® in Children With Von Willebrand Disease

Start: Aug 2010Est. completion: Aug 201317 patients
Phase 3Completed
NCT00404300BiocorpOptivate

Optivate in People With Von Willebrand Disease Undergoing Surgery

Start: Feb 2007Est. completion: Sep 200825 patients
Phase 3Terminated
NCT00387192BiocorpOptivate

A Study With OPTIVATE® in People With Von Willebrand Disease

Start: Nov 2006Est. completion: Sep 200826 patients
Phase 3Terminated
NCT02246881BiocorpOptivate®

A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.

Start: Oct 2001
Phase 3Completed
NCT00941616ParexelBiostate®

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

Start: Jun 2009Est. completion: Feb 201222 patients
Phase 2/3Completed
NCT00151125Pfizerrecombinant interleukin-11

Phase II Study of IL-11 (Neumega) in Von Willebrand Disease

Start: Jul 2004Est. completion: Dec 200712 patients
Phase 2Completed
NCT00816660TakedaRecombinant von Willebrand factor : recombinant FVIII

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Start: Dec 2008Est. completion: Aug 201032 patients
Phase 1Completed
NCT03521583CSL BehringVon Willebrand Disease in the Netherlands

Von Willebrand Disease in the Netherlands

Start: Jul 2019Est. completion: Jan 20221,100 patients
N/AUnknown
NCT04657887CSL BehringVoncento®

Registry of Patients With Von WilLEbrand Disease Treated With Voncento®

Start: Nov 2015Est. completion: Dec 2023135 patients
N/ACompleted
NCT01602419OctapharmaPatients using Wilate as standard of care

Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease

Start: Oct 2012Est. completion: Apr 2018120 patients
N/ACompleted
NCT00701545CSL BehringA Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

Start: Feb 2008Est. completion: Apr 200921 patients
N/ACompleted
NCT00510042CSL BehringNational Study of Moderate and Severe Von Willebrand Disease in the Netherlands

National Study of Moderate and Severe Von Willebrand Disease in the Netherlands

Start: Jul 2007Est. completion: Sep 20091,100 patients
N/ACompleted
NCT00557908CSL BehringVWF/FVIII products

The Von Willebrand Disease (VWD) International Prophylaxis Study

Start: Jun 2007Est. completion: Feb 2013105 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 2,850 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.